mRNA-1345-P901 Study: RSV Outcomes Study Extension (ROSE)
Latest Information Update: 29 Jan 2025
At a glance
- Drugs MRNA-1345 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Acronyms ROSE
- Sponsors Moderna Therapeutics
- 24 Jan 2025 Status changed from active, no longer recruiting to completed.
- 11 Jul 2024 Planned primary completion date changed from 30 Jun 2024 to 30 Jun 2026.
- 07 Jun 2023 Status changed from recruiting to active, no longer recruiting.